Other Events ·
Sionna Therapeutics announced a restructuring plan involving a 46% workforce reduction and the wind-down of its…
SIONSionna Therapeutics, Inc.
Sionna Therapeutics announced a restructuring plan involving a 46% workforce reduction and the wind-down of its SION-719 add-on program to focus resources on advancing the SION-451 and SION-2222 dual combination into a Phase 2a proof-of-concept trial expected to initiate in Q1 2027. The company estimates aggregate restructuring charges of approximately $6.4 million, including $5.3 million for severance and $0.7 million for contract close-outs. Concurrently, the Board approved an option repricing effective September 17, 2026, reducing exercise prices to the closing stock price to retain employees. Chief Business Officer Caroline Stark Beer was terminated without cause on September 15, 2026, while other executives assumed expanded roles. Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for cystic fibrosis.